viewPropanc Biopharma, Inc.

Propanc welcomes founding member back to scientific advisory board

Ralf Brandt returns to the board after temporarily stepping down in 2018

empty boardroom
PRP is designed to target tumors in pancreatic, ovarian and colorectal cancers

Propanc Biopharma Inc (OTCMKTS:PPCB) welcomed the co-inventor of its flagship drug back to its scientific advisory board, the company announced Monday.

Ralf Brandt, who helped the metastatic cancer treatment company develop its drug PRP, returns to the board after resigning in 2018.

He spent seven years on the board before stepping down to oversee the merger of vivoPharm, an oncology discovery company he co-founded.

READ: Propanc CEO looks to harness power of pancreatic enzymes in cancer fight

“We are pleased to welcome Dr. Brandt back to our scientific advisory board,” CEO James Nathanielsz said. “He played a pivotal role in advising the company, which enabled us to complete our preclinical development activities for the advancement of PRP to a first-in-human study in cancer patients. We look forward to his continued support and guidance, as we now focus our attention towards preparing for the planned clinical trial and progressing PRP through early stage clinical development.”

PRP is a treatment designed to target tumors in pancreatic, ovarian and colorectal cancers. Metastatic cancer, which Propanc focuses on, occurs when cancer cells spread to other areas of the body.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Propanc Biopharma, Inc.

Price: 0.08 USD

Market: OTCQB
Market Cap: $415.15 k

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Chaarat Gold's Dusty Nicol talks increase to reserves at Tulkubash

Chaarat Gold Holdings Ltd's (LON:CGH) Dusty Nicol caught up with Proactive London's Andrew Scott to talk through the increase in reserves that's been announced for its Tulkubash project in Kyrgyz Republic. It follows last year's 20,000 metre drilling programme. Proven & probable...

2 days, 4 hours ago

2 min read